CoChat
Sign Up
Cited by 30Transplantation: Methods and OutcomesMechanical Circulatory Support DevicesCongenital Heart Disease Studies

Cancer recurrence and mortality after pediatric heart transplantation for anthracycline cardiomyopathy: A report from the Pediatric Heart Transplant Study ( PHTS ) group

Bock, Matthew J., Pahl, Elfriede, Rusconi, Paolo G., Boyle, Gerard J., Parent, John J., Twist, Clare J., Kirklin, James K., Pruitt, Elizabeth +1 more·2017·Pediatric Transplantation
DOI 10.1111/petr.12923
Open this paper in CoChat — free account

Abstract

We aimed to determine whether malignancy after pediatric HT x for ACM affects overall post‐ HT x survival. Patients <18y listed for HT x for ACM in the PHTS database between 1993 and 2014 were compared to those with DCM . A 2:1 matched DCM cohort was also compared. Wait‐list and post‐ HT x survival, along with freedom from common HT x complications, were compared. Eighty subjects were listed due to ACM , whereas 1985 were listed for DCM . Although wait‐list survival was higher in the ACM group, post‐ HT x survival was lower for the ACM cohort. Neither difference persisted in the matched cohort analysis. Primary cause of death in the ACM group was infection, which was higher than the DCM group. Malignancy rates were not different. All ACM malignancies were due to PTLD without primary cancer recurrence or SMN . Long‐term graft survival after pediatric HT x for ACM is no different than for matched DCM peers, nor is there an increased risk of any malignancy. However, risk of infection and death from infection after HT x are higher in the ACM group. Further studies are needed to assess the effects of prior chemotherapy on susceptibility to infection in this group.

Integrity signals

Registry

Crossref · 10.1111/petr.12923

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Allogeneic heart transplants may be indicated for severe cases of anthracycline-induced heart failure.

    “Allogeneic heart transplants may be indicated for severe cases 165,166 .”

    From Osteosarcoma (2022) · cites this paper as [165]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Bock, M. J., Pahl, E., Rusconi, P. G., Boyle, G. J., Parent, J. J., Twist, C. J., Kirklin, J. K., Pruitt, E., & Bernstein, D.
Affiliations
  • Loma Linda University Children's Hospital (US)
  • Northwestern University (US)
  • University of Miami (US)
  • Cleveland Clinic (US)
  • Riley Hospital for Children (US)
  • Stanford Medicine (US)
  • University of Alabama at Birmingham (US)
Corresponding author
Bock, Matthew J.
ORCID
Venue
Pediatric Transplantation
Publisher
Wiley
Published
2017-04-04
Volume
21
Issue
5
ISSN
  • 1397-3142 (ISSN-L)
  • 1399-3046
DOI
10.1111/petr.12923
OpenAlex
W2604888898
Cited by
30
References
13
Citations by year
2026: 2 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 4 · 2021: 6 · 2020: 3 · 2019: 4 · 2018: 2 · 2017: 3
FWCI
3.36
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Pediatric Transplantation (publishedVersion)
  • PubMed (publishedVersion)
Funders
University of Alabama at Birmingham
Topics
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Physical Sciences › Engineering › Biomedical Engineering › Mechanical Circulatory Support Devices
  • Health Sciences › Medicine › Epidemiology › Congenital Heart Disease Studies
Keywords
pediatric heart transplantation, anthracycline-induced cardiomyopathy, tumor recurrence, post-transplant mortality, post-transplant survival, primary graft dysfunction, post-transplant lymphoproliferative disorder, dilated cardiomyopathy, graft survival, prior chemotherapy
MeSH terms
Adolescent, Antineoplastic Agents, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Infant, Infant, Newborn, Male, Cardiomyopathies, Neoplasm Recurrence, Local, Neoplasms, Postoperative Complications, Retrospective Studies, Survival Analysis, Case-Control Studies, Heart Transplantation, Anthracyclines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review